References
- Barry M, Usher C, Tilson L. Public drug expenditure in the Republic of Ireland. Expert Rev. Pharmacoecon. Outcomes Res. 10(3), 239–245 (2010).
- Usher C, Tilson L, Bennett K, Barry M. Cost containment interventions introduced on the community drugs schemes in Ireland – evaluation of expenditure trends using a national prescription claims database. Clin. Ther. 34(3), 632–639 (2012).
- Ioannides-Demos LL, Ibrahim JE, McNeil JJ. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics 20(9), 577–591 (2002).
- McGettigan P, McManus J, O’Shea B, Chan R, Feely J. Low rate of generic prescribing in the Republic of Ireland compared to England and Northern Ireland: prescribers’ concerns. Ir. Med. J. 90(4), 146–147 (1997).
- Brunt BH, Chappell N, Maclure M et al. Assessing the effectiveness of government and industry media campaigns on sentiors perceptions of a reference based pricing policies. J. App. Gerontol. 17, 276–295 (1998).
- Dylst P, Vulto A, Simoens S. The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev. Pharmacoecon. Outcomes Res. 11(6), 729–737 (2011).
- Drummond M, Jönsson B, Rutten F, Stargardt T. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur. J. Health Econ. 12(3), 263–271 (2011).
Websites
- Health Service Executive. Primary Care Reimbursement Service: statistical analysis of claims and payments (2010). www.hse.ie/eng/staff/PCRS/PCRS_Publications/claimsandpayments2010.pdf
- The Health Bill 2012. www.oireachtas.ie/viewdoc.asp?DocID=21567&&CatID=59